Evidence map›Paper›PMID 32866560›Full record

ReviewAdvanced drug delivery reviews2020

Targeting and therapeutic peptide-based strategies for polycystic kidney disease.

Jonathan Wang, Nirmalya Tripathy, Eun Ji Chung

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Nucleic acid drugs: recent progress and future perspectives.Signal transduction and targeted therapy · 2024
    Review
  7. Review
  8. Skin-Derived ABCB5International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jonathan WangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Nirmalya TripathyDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Eun Ji ChungDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA; Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA, USA; Department of Medicine, Division of Nephrology and Hypertension, University of Southern California, Los Angeles, CA, USA; Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, University of Southern California, Los Angeles, CA, USA. Electronic address: eunchung@usc.edu.
University of Southern California · US

Funding

A Revolutionary Approach for Polycystic Kidney Disease: Oral NanotherapeuticsDP2DK121328 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2018 to 2018
$2.4M
Multimodal Peptide Amphiphile Micelles for AtherosclerosisR00HL124279 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2016 to 2018
$747k
NHLBI NIH HHS R00 HL124279NIDDK NIH HHS DP2 DK121328
6 · The paper itself

Abstract

Polycystic kidney disease (PKD) is characterized by progressive cyst growth and is a leading cause of renal failure worldwide. Currently, there are limited therapeutic options available to PKD patients, and only one drug, tolvaptan, has been FDA-approved to slow cyst progression. Similar to other small molecule drugs, however, tolvaptan is costly, only moderately effective, and causes adverse events leading to high patient dropout rates. Peptides may mitigate many drawbacks of small molecule drugs, as they can be highly tissue-specific, biocompatible, and economically scaled-up. Peptides can function as targeting ligands that direct therapies to diseased renal tissue, or be potent as therapeutic agents themselves. This review discusses various aberrant signaling pathways in PKD and renal receptors that can be potential targets of peptide-mediated strategies. Additionally, peptides utilized in other kidney applications, but may prove useful in the context of PKD, are highlighted. Insights into novel peptide-based solutions that have potential to improve clinical management of PKD are provided.

Indexed as

AnimalsDisease ProgressionDrug Delivery SystemsHumansKidneyPeptidesPolycystic Kidney DiseasesSignal TransductionPeptidesChronic kidney diseasePeptidePolycystic kidney diseaseTargeted drug delivery

Identifiers

PMID32866560
PMCPMC7736157
OpenAlexW3081859031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.